Blood conservation in cardiac surgery: Guidelines and controversies

Transfusion and Apheresis Science

Volumn 50, Issue 1, 2014, Pages 20-25

  David Mazer, C ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; FIBRINOGEN CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; FIBRINOGEN; FIBRINOLYTIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ANEMIA; BLEEDING; BLOOD CONSERVATION; BLOOD TRANSFUSION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; ERYTHROCYTE; ERYTHROCYTE PRESERVATION; ERYTHROCYTE TRANSFUSION; FIBRINOLYTIC THERAPY; HEART SURGERY; HEMATOCRIT; HUMAN; KIDNEY FAILURE; MINIMALLY INVASIVE PROCEDURE; MODIFIED ULTRAFILTRATION; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; REVIEW; RISK REDUCTION; THROMBOCYTE COUNT; ADVERSE EFFECTS; BLOOD LOSS, SURGICAL; BLOOD STORAGE; CHEMICALLY INDUCED; CHEMISTRY; HEMOSTASIS; PERIOPERATIVE PERIOD; PROCEDURES; RISK;

ANEMIA; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; BLOOD PRESERVATION; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; FACTOR VIIA; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEMOSTASIS; HUMANS; PERIOPERATIVE PERIOD; RECOMBINANT PROTEINS; RISK;

EID: 84897027159     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.12.008     Document Type: Review

References (67)

1. Karkouti K., Wijeysundera D.N., Yau T.M., et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004, 44:1453-1462.
2. Freedman J., Luke K., Escobar M., Vernich L., Chiavetta J.A. Experience of a network of transfusion coordinators for blood conservation (Ontario Transfusion Coordinators [ONTraC]). Transfusion 2008, 48:237-250.
3. Shander A., Javidroozi M., Ozawa S., Hare G.M. What is really dangerous: anaemia or transfusion?. Br J Anaesth 2011, 107(Suppl 1):i41-i59.
4. Moskowitz D.M., McCullough J.N., Shander A., et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective?. Ann Thorac Surg 2010, 90:451-458.
5. Bennett-Guerrero E., Zhao Y., O'Brien S.M., et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 2010, 304:1568-1575.
6. Despotis G.J., Filos K.S., Zoys T.N., Hogue C.W., Spitznagel E., Lappas D.G. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996, 82:13-21.
7. Ferraris V.A., Ferraris S.P. Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Tex Heart I J 1995, 22:216-230.
8. Ferraris V.A., Ferraris S.P., Saha S.P., et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the society of thoracic surgeons and the society of cardiovascular anesthesiologists clinical practice guideline. Ann Thorac Surg 2007, 83:S27-S86.
9. Klein H.G., Spahn D.R., Carson J.L. Red blood cell transfusion in clinical practice. Lancet 2007, 370:415-426.
10. Snyder-Ramos S.A., Mohnle P., Weng Y.S., et al. The ongoing variability in blood transfusion practices in cardiac surgery. Transfusion 2008, 48:1284-1299.
11. Takami Y., Masumoto H. Predictors of allogenic blood transfusion in elective cardiac surgery after preoperative autologous blood donation. Surg Today 2009, 39:306-309.
12. Ferraris V.A., Brown J.R., Despotis G.J., et al. 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011, 91:944-982.
13. Karkouti K., Wijeysundera D.N., Beattie W.S. Reducing Bleeding in Cardiac Surgery (RBC) Investigators. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation 2008, 117:478-484.
14. Kulier A., Levin J., Moser R., et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007, 116:471-479.
15. Spahn D.R., Casutt M. Eliminating blood transfusions: new aspects and perspectives. Anesthesiology 2000, 93:242-255.
16. Shander A., Moskowitz D.M., Javidroozi M. Blood conservation in practice: an overview. Brit J Hosp Med (Lond) 2009, 70:16-21.
17. Shander A., Goodnough L.T. Objectives and limitations of bloodless medical care. Curr Opin Hematol 2006, 13:462-470.
18. Triulzi D.J. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg 2009, 108:770-776.
19. Leal-Noval S.R., Munoz-Gomez M., Arellano-Orden V., et al. Impact of age of transfused blood on cerebral oxygenation in male patients with severe traumatic brain injury. Crit Care Med 2008, 36:1290-1296.
20. Vamvakas E.C., Carven J.H. Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. Transfusion 2002, 42:107-113.
21. van de Watering L., Lorinser J., Versteegh M., Westendord R., Brand A. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion 2006, 46:1712-1718.
22. Koch C.G., Li L., Sessler D.I., et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008, 358:1229-1239.
23. Solomon SB, Wang D, Sun J et al. Mortality increases after massive exchange transfusion with older stored blood in canines with experimental pneumonia. Blood; 2012 [Epub ahead of print].
24. Dunning J., Versteegh M., fabbri A., et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008, 34:73-92.
25. Likosky D.S., Fleischer F., Groom R.C., et al. Effect of the perioperative blood transfusion and blood conservation in cardiac surgery clinical practice guidelines of the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists upon clinical practices. J Ext Corp Technol 2010, 42:114-121.
26. Hall R., Mazer C.D. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg 2011, 112:292-318.
27. Eagle K.A., Guyton R.A., Davidoff R., et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). J. Am. Coll. Cardiol 2004, 44:e213-e310.
28. Hillis L.D., Smith P.K., Anderson J.L., et al. ACCF/AHA guideline for coronary artery bypass graft surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011, 124:e652-e735.
29. Korte W., Cattaneo M., Chassot P.G., et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011, 105:743-749.
30. Levi M., Eerenberg E., Kamphuisen P.W. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost 2011, 9:1705-1712.
31. Levy J.H., Key N.S., Azran M.S. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology 2010, 113:726-745.
32. Wittkowsky A.K. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis 2010, 29:182-191.
33. Hankey G.J., Eikelboom J.W. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011, 123:1436-1450.
34. Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010.
35. Dunkley S., Phillips L., McCall P., et al. Recombinant activated Factor VII in cardiac surgery:experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg 2008, 85:836-844.
36. Karkouti K., Beattie W.S., Wijeysundera D.N., et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005, 45:26-34.
37. Karkouti K., Beattie W.S., Crowther M.A., et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anaesth 2007, 54:573-582.
38. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295:293-298.
39. Raivio P., Suojaranta-Ylinen R., Kuitunen A.H. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg 2005, 80:66-71.
40. Gill R., Herbertson M., Vuylsteke A., et al. Safety and efficacy of recombinant activated Factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009, 120:21-27.
41. Simpson E., Lin Y., Stanworth S., Birchall J., Doree C., Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane. Database. Syst. Rev. 2012, 3:CD005011.
42. Levi M., Levy J.H., Andersen H.F., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. NEngl J Med 2010, 363:1791-1800.
43. Moltzan C.J., Anderson D.A., Callum J., et al. The evidence for the use of recombinant Factor VIIa in massive bleeding: development of a transfusion policy framework. Transf Med 2008, 18:112-120.
44. Alport E., Callum J., Nahirniak S., Eurich B., Hume H. Cryoprecipitate use in 25 Canadian hospitals: commonly used outside of the published guidelines. Transfusion 2008, 48:2122-2127.
45. Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Skrtic S, Jeppsson A. Prophylactic fibrinogen infusion in cardiac surgery patients: effects on biomarkers of coagulation, fibrinolysis, and platelet function. Clin Appl Thromb Hemost; 2010.
46. Rahe-Meyer N., Solomon C., Winterhalter M., et al. Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery. J Thorac Cardiovasc Surg 2009, 138:694-702.
47. Karlsson M., Ternstrom L., Hyllner M., et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Hemost 2009, 102:137-144.
48. Rahe-Meyer N., Pichlmaier M., Haverich A., et al. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth 2009, 102:785-792.
49. Mangano D.T., Tudor I.C., Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006, 354:353-365.
50. Mangano D.T., Miao Y., Vuylsteke A., et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007, 297:471-479.
51. Shaw A.D., Stafford-Smith M., White W.D., et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008, 358:784-793.
52. Schneeweiss S., Seeger J.D., Landon J., Walker A.M. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008, 358:771-783.
53. Fergusson D.A., Hebert P.C., Mazer C.D., et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008, 358:2319-2331.
54. Martin K., Wiesner G., Breuer T., Lange R., Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 2008, 107:1783-1790.
55. Murkin J.M., Falter F., Granton J., Young B., Burt C., Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010, 110:350-353.
56. Lecker I., Wang D.S., Romaschin A.D., Peterson M., Mazer C.D., Orser B.A. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012, 122:4654-4666.
57. Alghamdi A.A., Albanna M.J., Guru V., Brister S.J. Does the use of erythropoietin reduce the risk of exposure to allogeneic blood transfusion in cardiac surgery? A systematic review and meta-analysis. J Card Surg 2006, 21:320-326.
58. Corwin H.L., Gettinger A., Fabian T.C., et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357:965-976.
59. Song Y.R., Lee T., You S.J., et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009, 30:253-260.
60. Sowade O., Ziemer S., Sowarde B., et al. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med 1997, 129:376-383.
61. Weltert L., D'Alessandro S., Nardella S., et al. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg 2010, 139:621-627.
62. Yoo Y.C., Shim J.K., Kim J.C., Jo Y.Y., Lee J.H., Kwak Y.L. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011, 115:929-937.
63. D'Ambra M.N., Gray R.J., Hillman R., et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997, 64:1686-1693.
64. Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011, 17:6373-6380.
65. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
66. Solomon S.D., Uno H., Lewis E.F., et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. NEngl J Med 2010, 363:1146-1155.
67. DeAnda A., Baker K.M., Roseff S.D., et al. Developing a blood conservation program in cardiac surgery. Am J Med Qual 2006, 21:230-237.